Trial results for a real-world study investigating tofacitinib treatment in Rheumatoid Arthritis patients were posted on ClinicalTrials.gov on 2025-06-08, with 198 participants enrolled. The study aimed to identify predictors of response and describe treatment patterns and effects on patient quality of life and physical function in a real-world setting.
Background
Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the joints, leading to pain, swelling, stiffness, and potential joint damage. Effective management aims to reduce disease activity, prevent disability, and improve quality of life. Tofacitinib, an oral Janus kinase (JAK) inhibitor, is an established treatment for RA. Real-world studies, like this one, are crucial for understanding how treatments perform in routine clinical practice, complementing data from controlled clinical trials by reflecting a broader patient population and diverse treatment patterns.
Trial design
This completed non-interventional, multi-center study enrolled 198 participants diagnosed with Rheumatoid Arthritis. The primary aim was to identify baseline characteristics that predict response to tofacitinib treatment at 6 months. Secondary aims included describing the real-world treatment patterns of RA patients prescribed tofacitinib, assessing its effect on patient quality of life and physical function, and evaluating healthcare resource utilization and costs in Greece.
Key results
The study reported several key measurements related to disease activity and functional status:
- Percentage of Participants With Remission and Low Disease Activity (LDA) at Month 6 Assessed Using 28-Joint Disease Activity Score C-Reactive Protein (DAS28-4 CRP):
- One measurement showed 29.6% of participants.
- Another measurement showed 41.4% of participants.
- Percentage of Participants With Remission and LDA at Month 12 Assessed Using DAS28-4 CRP:
- One measurement showed 33.3% of participants.
- Another measurement showed 55.3% of participants.
- Change From Baseline in DAS28-4 (ESR) and DAS28-4 (CRP):
- For DAS28-4 (ESR), a mean change of -1.25 (Standard Deviation 1.38) was observed.
- Another mean change for DAS28-4 (ESR) was -1.73 (Standard Deviation 1.46).
- A third mean change for DAS28-4 (ESR) was -1.42 (Standard Deviation 1.58).
- For DAS28-4 (CRP), a mean change of -1.47 (Standard Deviation 1.40) was observed.
- Another mean change for DAS28-4 (CRP) was -1.15 (Standard Deviation 1.47).
- A third mean change for DAS28-4 (CRP) was -1.58 (Standard Deviation 1.61).
- Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Months 3, 6 and 12:
- At an unspecified time point, a mean change of -0.25 (Standard Deviation 0.56) was observed.
- At another unspecified time point, a mean change of -0.40 (Standard Deviation 0.60) was observed.
What this means
The results from this real-world study provide valuable insights into the effectiveness of tofacitinib in patients with Rheumatoid Arthritis in a clinical practice setting. The observed percentages of participants achieving remission and low disease activity, as measured by DAS28-4 CRP at 6 and 12 months, suggest that tofacitinib contributes to meaningful disease control. Furthermore, the reported reductions in DAS28-4 (ESR and CRP) and HAQ-DI scores indicate improvements in disease activity and physical function. This data supports the continued use of tofacitinib in RA management and offers further evidence of its impact on patient outcomes outside of highly controlled trial environments, aligning with the study's goal of understanding real-world treatment patterns and effects.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04079920, titled "Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis Patients", were posted on 2025-06-08 on clinicaltrials.gov.